Journal of Volgograd State Medical UniversityJournal of Volgograd State Medical UniversityВестник Волгоградского государственного медицинского университета1994-94801994-9499Volgograd State Medical University63028210.19163/1994-9480-2024-21-1-19-25Review ArticlesОбзорные статьиReview ArticleProspects for the application of angiopoetin-like proteins type 3 and 4 for early and accurate diagnosis of kidney damageПерспективы применения ангиопоэтин-подобных белков 3-го и 4-го типов для ранней и точной диагностики повреждения почекhttps://orcid.org/0000-0002-4500-7172AleksandrovV. A.АлександровВладислав Андреевич
Russian Federation

Assistant of the Department of Hospital Therapy, Volgograd State Medical University; Junior Research Associate, Research Institute of Clinical and Experimental Rheumatology named after А.B. Zborovsky

ассистент кафедры госпитальной терапии, Волгоградский государственный медицинский университет; младший научный сотрудник Научно-исследовательского института клинической и экспериментальной ревматологии имени А.Б. Зборовского

imlab@mail.ruVolgograd State Medical UniversityВолгоградский государственный медицинский университетResearch Institute of Clinical and Experimental Rheumatology named after А.B. ZborovskyНаучно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. Зборовского1504202421119251204202412042024Copyright ©; 2024, Aleksandrov V.A.Copyright ©; 2024, Александров В.А.2024Aleksandrov V.A.Александров В.А.https://creativecommons.org/licenses/by/4.0https://journals.eco-vector.com/1994-9480/article/view/630282

Currently, there is an active accumulation of new data indicating the involvement of the angiopoietin-like proteins family in many physiological and pathophysiological processes, such as lipid metabolism, glucose metabolism, angiogenesis, development of inflammatory and malignant processes, etc. In this review the latest data on a role of angiopoetin-like proteins of the 3rd and 4th types in regulation of lipidic exchange, about connection of the studied proteins with metabolic frustration, including pathology of kidneys and also about possible therapeutic use of inhibitors of angiopoetin-like proteins are generalized at a dislipidemiya and a proteinuria.

В настоящее время продолжаются активно накапливаться новые данные, свидетельствующие об участии семейства ангиопоэтин-подобных белков во многих физиологических и патофизиологических процессах, таких как липидный обмен, метаболизм глюкозы, ангиогенез, развитие воспалительных и злокачественных процессов и др. В этом обзоре обобщаются последние данные о роли ангиопоэтин-подобных белков 3-го и 4-го типов в регуляции липидного обмена, о связи изучаемых белков с метаболическими расстройствами, включая патологию почек, а также о возможном терапевтическом применении ингибиторов ангиопоэтин-подобных белков при дислипидемии и протеинурии.

angiopoietin-like proteinskidney damagedyslipidemiaproteinuriaglomerular filtration rateангиопоэтин-подобные белкипоражение почекдислипидемияпротеинурияскорость клубочковой фильтрацииHara S., Kobayashi N., Sakamoto K. et al. Podocyte injury-driven lipid peroxidation accelerates the infiltration of glomerular foam cells in focal segmental glomerulosclerosis. American Journal Pathology. 2015;185(8):2118–2131. doi: 10.1016/j.ajpath.2015.04.007.Kersten S. New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk. Current Opinion in Lipidology. 2019;30(3):205–211. doi: 10.1097/MOL.0000000000000600.Dijk W., Kersten S. Regulation of lipid metabolism by angiopoietin-like proteins. Current Opinion in Lipidology. 2016;27(3):249–256. doi: 10.1097/MOL.0000000000000290.Santulli G. Angiopoietin-like proteins: A comprehensive look. Frontiers in Endocrinology (Lausanne). 2014;5:4. doi: 10.3389/fendo.2014.00004.Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nature Reviews Endocrinology. 2017;13(12):731–739. doi: 10.1038/nrendo.2017.119.Thorin E., Labbé P., Lambert M. et al. Angiopoietin-like proteins: cardiovascular biology and therapeutic targeting for the prevention of cardiovascular diseases. Canadian Journal of Cardiology. 2023:S0828-282X(23)00452-X. doi: 10.1016/j.cjca.2023.06.002.Akoumianakis I., Zvintzou E., Kypreos K., Filippatos T.D. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Current Atherosclerosis Reports. 2021;23(5):20. doi: 10.1007/s11883-021-00914-7.Wang X., Musunuru K. Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing. JACC: Basic to Translational Science. 2019;4(6):755–762. doi: 10.1016/j.jacbts.2019.05.008.Khetarpal S.A., Vitali C., Levin M.G. et al. Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins. PLoS Genetics. 2021;17(9):e1009802. doi: 10.1371/ррjournal.pgen.1009802.Biterova E., Esmaeeli M., Alanen H.I. et al. Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease. Scientific Reports. 2018;8(1):6752. doi: 10.1038/s41598-018-25237-7.Sylvers-Davie K.L., Davies B.S.J. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. American Journal of Physiology-Endocrinology and Metabolism. 2021;321(4):E493–E508. doi: 10.1152/ajpendo.00195.2021.Jin N., Matter W.F., Michael L.F. et al. The Angiopoietin-Like Protein 3 and 8 Complex Interacts with Lipoprotein Lipase and Induces LPL Cleavage. ACS Chemical Biology. 2021;16(3):457–462. doi: 10.1021/acschembio.0c00954.Ge H., Yang G., Huang L. et al. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. Journal of Biological Chemistry. 2004;279(3):2038–2045. doi: 10.1074/jbc.M307583200.Lei X., Shi F., Basu D. et al. Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. Journal of Biological Chemistry. 2011;18:15747–15756. doi: 10.1074/jbc.M110.217638.Knowles H.J. Multiple Roles of Angiopoietin-Like 4 in Osteolytic Disease. Frontiers in Endocrinology (Lausanne). 2017;8:80. doi: 10.3389/fendo.2017.00080.Grootaert C., Van de Wiele T., Verstraete W. et al. Angiopoietin-like protein 4: health effects, modulating agents and structure-function relationships. Expert Review of Proteomics. 2012;9(2):181–199. doi: 10.1586/epr.12.12.Fernández-Hernando C., Suárez Y. ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis. Current Opinion in Hematology. 2020;27(3):206–213. doi: 10.1097/MOH.0000000000000580.Mandard S., Zandbergen F., Tan N.S. et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. Journal of Biological Chemistry. 2004;279(33):34411–34420. doi: 10.1074/jbc.M403058200.Aryal B., Price N.L., Suarez Y., Fernández-Hernando C. ANGPTL4 in Metabolic and Cardiovascular Disease. Trends in Molecular Medicine. 2019;25:723–734. doi: 10.1016/j.molmed. 2019.05.010.Mattijssen F., Kersten S. Regulation of triglyceride metabolism by Angiopoietin-like proteins. Biochimica et Biophysica Acta. 2012;1821(5):782–789. doi: 10.1016/j.bbalip.2011.10.010.Zhu P., Goh Y.Y., Chin H.F. et al. Angiopoietin-like 4: a decade of research. Bioscience Reports. 2012;32(3):211–219. doi: 10.1042/BSR20110102.Gyebi L., Soltani Z., Reisin E. Lipid nephrotoxicity: new concept for an old disease. Current Hypertension Reports. 2012;14(2):177–181. doi: 10.1007/s11906-012-0250-2.Merscher-Gomez S., Guzman J., Pedigo C.E. et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes. 2013;62(11):3817–3827. doi: 10.2337/db13-0399.Pu X., Sale M., Yang F. et al. Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia. CPT: Pharmacometrics & Systems Pharmacology. 2021;10:1412–1421. doi: 10.1002/psp4.12711.Surma S., Romańczyk M., Filipiak K.J. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiology Journal. 2023;30(1):131–142. doi: 10.5603/CJ.a2021.0006.Liu J., Gao X., Zhai Y. et al. A novel role of angiopoietin-like-3 associated with podocyte injury. Pediatric Research. 2015;77(6):732–739. doi: 10.1038/pr.2015.38.Li G., Lu D., Wang J. et al. ANGPTL3 is involved in kidney injury in high-fat diet-fed mice by suppressing ACTN4 expression. Lipids in Health and Disease. 2022;21(1):90. doi: 10.1186/s12944-022-01700-3.Lin Y., Rao J., Zha X.L., Xu H. Angiopoietin-like 3 induces podocyte F-actin rearrangement through integrin α(V)β3/FAK/PI3K pathway-mediated Rac1 activation. BioMed Research International. 2013;2013:135608. doi: 10.1155/2013/135608.Perico L., Conti S., Benigni A., Remuzzi G. Podocyte-actin dynamics in health and disease. Nature Reviews Nephrology. 2016;12(11):692–710. doi: 10.1038/nrneph.2016.127.Gao X., Suo Y., Zhang M. et al. Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria. Lipids in Health and Diseases. 2019;18(1):116. doi: 10.1186/s12944-019-1052-1.Zhong F., Liu S., Li Y. et al. ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome. Lipids in Health and Diseases. 2022;21(1):38. doi: 10.1186/s12944-022-01632-y.Dai R., Liu H., Han X. et al. Angiopoietin-like-3 knockout protects against glomerulosclerosis in murine adriamycin-induced nephropathy by attenuating podocyte loss. BMC Nephrology. 2019;20(1):185. doi: 10.1186/s12882-019-1383-1.Zhao Y., Goto M., Vaziri N.D. et al. RNA Interference Targeting Liver Angiopoietin-Like Protein 3 Protects from Nephrotic Syndrome in a Rat Model Via Amelioration of Pathologic Hypertriglyceridemia. Journal of Pharmacology and Experimental Therapeutics. 2021;376(3):428–435. doi: 10.1124/jpet.120.000257.Wen F., Liu J., Dai R. et al. Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children. Frontiers in Pediatrics. 2023;11:1113484. doi: 10.3389/fped.2023.1113484.Park C.Y, Moon J., Jo G. et al. The association between genetic variants of angiopoietin-like 3 and risk of diabetes mellitus is modified by dietary factors in Koreans. Scientific Reports. 2019;9(1):766. doi: 10.1038/s41598-018-36581-z.Aghasizadeh M., Zare-Feyzabadi R., Kazemi T. et al. A haplotype of the ANGPTL3 gene is associated with CVD risk, diabetes mellitus, hypertension, obesity, metabolic syndrome, and dyslipidemia. Gene. 2021;782:145525. doi: 10.1016/j.gene.2021.14552.Azadi S.M., Fadaei R., Omid-Shafaat R. et al. Elevated angiopoietin-like protein 3 serum levels in diabetic nephropathy patients and its association with renal function and lipid profile. BMC Nephrology. 2023;24(1):172. doi: 10.1186/s12882-023-03214-1.Ma Q., Hu X., Liu F. et al. A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice. Frontiers in Immunology. 2022;13:1011442. doi: 10.3389/fimmu.2022.1011442.Han X., Dai R., Zhai Y. et al. Anti-proteinuria effect of antibody against ANGPTL3 coil-coiled domain on adriamycin-induced nephropathy in mice. Biochemical and Biophysical Research Communications. 2019;516(3):812–818. doi: 10.1016/ j.bbrc.2019.06.065.Ma Y., Liu J., Liu H. et al. Podocyte protection by Angptl3 knockout via inhibiting ROS/GRP78 pathway in LPS-induced acute kidney injury. International Immunopharmacology. 2022;105:108549. doi: 10.1016/j.intimp.2022.108549.Lv Q., Han X., Ni J. et al. Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage. Cell Death and Disease. 2022;13(10):867. doi: 10.1038/s41419-022-05313-7.Aklilu A.M. Diagnosis of Chronic Kidney Disease and Assessing Glomerular Filtration Rate. Medical Clinics of North America. 2023;107(4):641–658. doi: 10.1016/j.mcna.2023.03.001.Gao Y., Ma Y., Xie D., Jiang H. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model. International Immunopharmacology. 2022;107:108711. doi: 10.1016/j.intimp.2022.108711.Herman-Edelstein M., Scherzer P., Tobar A. et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. Journal of Lipid Research. 2014;55(3):561–572. doi: 10.1194/jlr.P040501.Bano G., Imam M.T., Bajpai R. et al. Expression of angiopoetin-like protein-4 and kidney injury molecule-1 as preliminary diagnostic markers for diabetes-related kidney disease: a single center-based cross-sectional study. Journal of Personalized Medicine. 2023;13(4):577. doi: 10.3390/jpm13040577.Vanarsa K., Soomro S., Zhang T. et al.Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. Annals of Rheumatic Diseases. 2020;79(10):1349–1361. doi: 10.1136/annrheumdis-2019-216312.Aleksandrov V.A., Shilova L.N., Aleksandrov A.V. The role of angiopoietin-like proteins in the development of renal dysfunction in patients with rheumatoid arthritis and metabolic changes. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta = Journal of Volgograd State Medical University. 2020;4(76): 37–41. (In Russ.). doi: 10.19163/1994-9480-2020-4(76)-37-41.Clement L.C., Avila-Casado C., Macé C. et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nature Medicine. 2011;17(1):117–122. doi: 10.1038/nm.2261.Ma J., Chen X., Li J.S. et al. Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy. Endocrine. 2015;49(2):373–384. doi: 10.1007/s12020-014-0486-5.Gao X., Zhang M., Feng W. et al. Alteration of angiopoietin-like protein 4 levels in serum or urine correlate with different biochemical markers in hyperlipidemia-related proteinuria. BioMed Research International. 2020;2020:5281251. doi: 10.1155/2020/5281251.Baranowski T., Kralisch S., Bachmann A. et al. Serum levels of the adipokine fasting-induced adipose factor/angiopoietin-like protein 4 depend on renal function. Hormone and Metabolic Research. 2011;43(2):117–120. doi: 10.1055/s-0030-1267917.Mahmood D., Makoveichuk E., Nilsson S. et al. Response of angiopoietin-like proteins 3 and 4 to hemodialysis. International Journal of Artificial Organs. 2014;37(1):13–20. doi: 10.5301/ijao.5000252.Chugh S.S., Macé C., Clement L.C. et al. Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease. Frontiers in Pharmacology. 2014;5:23. doi: 10.3389/fphar. 2014.00023.Macé C., Chugh S.S. Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics. Journal of American Society Nephrology. 2014;25(11):2393–2398. doi: 10.1681/ASN.2014030267.Del Nogal-Avila M., Donoro-Blazquez H., Saha M.K. et al. Novel therapeutic approaches for chronic kidney disease due to glomerular disorders. American Journal of Physiology – Renal Physiology. 2016;311(1):F63–65. doi: 10.1152/ajprenal.00245.2016.Meng X., Zou H., Li D. et al. Association of Circulating ANGPTL8 Levels With Renal Dysfunction: A Case-Control Study. Front Public Health. 2021;9:710504. doi: 10.3389/fpubh.2021.710504.